Hepatic Encephalopathy Staging Tool for Reproducible Severity Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tools for evaluating the severity of hepatic encephalopathy lack precision and reproducibility, particularly in distinguishing between grades 1 and 2, leading to inconsistent treatment outcomes.
Innovation Solution
A novel hepatic encephalopathy staging tool (HEST) comprising four criteria, including factual questions and observations of asterixis and symptoms, to assess severity and guide medicament administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the West Haven Criteria is used to diagnose and grade hepatic encephalopathy, then a standard scale for assessment is provided, but the distinction between grades 1 and 2 lacks precision and reproducibility due to subjective interpretation of neurological symptoms
Solution Approach 1:
The assessment tool is segmented into multiple distinct criteria: (1) factual questions assessment, (2) asterixis observation, (3) symptom observation (stupor, drowsiness, confusion, disorientation), and (4) coma detection. Each criterion independently contributes to the overall HE stage determination, eliminating reliance on a single subjective assessment and improving both ease of use and measurement precision.
2Reliability
If current HE evaluation tools are used, then a diagnostic framework is available, but treatment outcomes are inconsistent due to lack of reproducibility in severity classification
Solution Approach 1:
The patent implements a feedback mechanism where the four assessment criteria continuously monitor HE severity, and treatment decisions are adjusted based on the staged results. This closed-loop system ensures consistent application of treatment protocols according to objectively determined HE stages, improving both diagnostic reliability and treatment productivity.
Solution Approach 2:
The patent transitions from subjective neurological symptom interpretation to objective parameter-based assessment including factual question accuracy, presence/absence of asterixis, specific observable symptoms, and coma status. These quantifiable parameters enable consistent staging across different clinicians and settings, directly improving reproducibility and subsequent treatment effectiveness.
Data Source
AI summary
The present disclosure relates to methods of treating or ameliorating hepatic encephalopathy (HE), including assessing the severity of HE in a patient suffering from HE, or the determining the presence or occurrence of an overt hepatic encephalopathy event. In particular, some aspects of the methods use a novel Hepatic Encephalopathy Staging Tool (HEST), which includes a set of criteria to categorize the HE into different stages and provide guidance on effective treatments based on the severity of the HE. Other aspects of the methods use an Overt Hepatic Encephalopathy Screening Tool (O-HEST) to determine whether an OHE event is occurring or has occurred and provide guidance on proper medical attention and change in treatment.